LifeMD (NASDAQ:LFMD) Given New $10.00 Price Target at HC Wainwright

LifeMD (NASDAQ:LFMD) had its target price lifted by HC Wainwright from $9.00 to $10.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research analysts have also recently issued reports on LFMD. Wall Street Zen cut shares of LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Lake Street Capital cut their price target on LifeMD from $14.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. BTIG Research reiterated a “buy” rating and set a $10.00 price objective on shares of LifeMD in a research note on Tuesday. KeyCorp decreased their price objective on LifeMD from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Wednesday, November 19th. Finally, B. Riley Financial lowered their target price on LifeMD from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Six equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.57.

LifeMD Trading Up 3.8%

Shares of NASDAQ:LFMD opened at $4.06 on Wednesday. LifeMD has a twelve month low of $2.56 and a twelve month high of $15.84. The company has a market cap of $195.43 million, a PE ratio of 15.62 and a beta of 1.92. The company’s 50 day moving average is $3.31 and its 200 day moving average is $4.56.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings data on Monday, March 9th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.03). The business had revenue of $46.87 million for the quarter, compared to analyst estimates of $48.57 million. LifeMD had a net margin of 6.58% and a negative return on equity of 497.20%. Equities research analysts predict that LifeMD will post -0.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC raised its position in shares of LifeMD by 110.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after acquiring an additional 2,452 shares during the period. Quarry LP acquired a new stake in shares of LifeMD during the 3rd quarter valued at about $52,000. King Wealth Management Group purchased a new position in shares of LifeMD in the 3rd quarter valued at about $68,000. Legal & General Group Plc raised its holdings in LifeMD by 187.4% in the 2nd quarter. Legal & General Group Plc now owns 10,144 shares of the company’s stock worth $138,000 after purchasing an additional 6,614 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in LifeMD in the fourth quarter valued at approximately $36,000. Hedge funds and other institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.